|View printer-friendly version|
|June 30, 2005 11:32 a.m.|
|Teva Announces Final Approval Of Mirtazapine Orally Disintegrating Tablets|
Jerusalem, Israel, June 30, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S Food and Drug Administration has granted final approval for the company's ANDA for Mirtazapine Orally Disintegrating Tablets (ODT), 15 mg, 30 mg and 45 mg. As one of the companies first to file a Paragraph IV certification for the 45 mg tablet, Teva expects to share 180-day marketing exclusivity for this strength. Shipment of this product is expected to begin in the near future.